We have previously shown that BCR/ABL, a fusion protein generated by the t(9;22)(q34;q11) translocation found in the vast majority of chronic myelogenous leukemia (CML), cooperates with AML1/MDS1/EVI1 (AME), a fusion transcription factor generated by a t(3;21)(q26;q22) translocation identified as a secondary mutation in some cases of CML during the blast phase (CML-BC), in the rapid induction of an acute myelogenous leukemia (AML) in mice. In this study, we evaluated the leukemogenic potential of EVI1-, MDS1/EVI1-and AML1-related oncoproteins (AML1D, AML1/MDS1). We found that ectopic expression of either EVI1 or MDS1/EVI1 impaired hematopoiesis. However, neither EVI1 nor MDS1/EVI1 was sufficient for inducing AML in mice, although EVI1 did induce some hematologic neoplasia other than AML with a low efficiency. In addition, unlike AME, none of the EVI1-or AML1-related oncoproteins examined were capable of fully cooperating with BCR/ABL in the induction of AML. The results indicate that both the AML1 and EVI1 oncogenic components are required for the leukemogenic potential of AME and for the cooperation of AME and BCR/ABL in the induction of AML.
Introduction
The development of acute myelogenous leukemia (AML) and the blast phase of chronic myelogenous leukemia (CML-BC), both of which are characterized by an uncontrolled growth and a block in differentiation of myeloid cells, are multistep processes that involve multiple genetic abnormalities (Fialkow et al., 1991; Jacobs, 1991; Faderl et al., 1999) . Mutations or aberrant expression of both transcription factors and signal transducers that play important roles in hematopoiesis and organismal development are frequently found in these myeloblastic leukemias (Gilliland and Griffin, 2002; Scandura et al., 2002) . However, the molecular mechanisms by which these genetic alterations act in leukemogenesis are poorly understood.
We and others have previously shown that the expression of BCR/ABL, a fusion protein with an elevated protein tyrosine kinase activity generated by the t(9;22)(q34;q11) translocation found in the vast majority of CML patients (Kurzrock et al., 1988) , efficiently induces a myeloproliferative disorder (MPD) in mice resembling human CML in the chronic phase (Pear et al., 1998; Zhang and Ren, 1998; Li et al., 1999) . We have also found that AML1/MDS1/EVI1 (AME), a fusion transcription factor generated by a t(3;21)(q26;q22) translocation, identified as a secondary mutation in some cases of CML-BC and in therapy-related myelodysplastic syndrome (MDS) and AML (Nucifora, 1997) , induces an AML in mice with a greatly extended latency (5-13 months) (Cuenco et al., 2000) . During the 4-month preleukemia stage in mice, the expression of AME does not block myeloid differentiation despite causing some impairments in hematopoiesis (Cuenco and Ren, 2001 ). This indicates that blocking myeloid cell differentiation and induction of AML by AME requires the cooperation of additional genetic abnormalities. We have further shown that the coexpression of BCR/ABL and AME induces a rapid myeloblastic leukemia (Cuenco and Ren, 2001 ). These results suggest that cooperation between mutations that activate protein tyrosine kinase signaling and those that disrupt hematopoietic gene transcription is involved in blocking myeloid differentiation and the induction of myeloblastic leukemia. Recent clinical findings that both activated protein tyrosine kinases, such as FLT3 and c-Kit, and transcription factor fusion proteins are present in many cases of AML further support this hypothesis (Gilliland and Griffin, 2002) . The cooperation between BCR/ABL and AME in the induction of myeloblastic leukemia should, therefore, be a model for further investigating the common mechanism of both CML-BC and AML.
Both fusion partners of AME -AML1 and MDS1/ EVI1 -encode transcription factors and are themselves targets of a variety of genetic abnormalities found in AML and CML-BC. AML1 (also termed as CBFA2 or RUNX1) is a DNA-binding subunit of the core binding factor (CBF) and functions as a heterodimer with the non-DNA binding subunit CBFb. Gene targeting experiments demonstrate that both AML1/RUNX1 and CBFb play an essential role in definitive hematopoiesis and blood vessel development (Okuda et al., 1996; Wang et al., 1996) . The haploinsufficiency of AML1/RUNX1 found in familial thrombocytopenia with a propensity to develop AML suggests that CBFs also have tumor suppression functions (Song et al., 1999) . The EVI1 gene encodes a zinc-finger-containing transcription factor and was originally identified as a common site of retroviral integration in murine myeloid tumors (Mucenski et al., 1988) . EVI1 has been found expressed only in very early hematopoietic stem cells and in nonhematopoietic cells (Fears et al., 1996; Phillips et al., 2000) . MDS1/EVI1 is a longer alternatively spliced form of EVI1 and the PR domain in MDS1/EVI1 inhibits many functions of EVI1 (Nucifora, 1997).
The AML1 gene has been frequently found to be fused to the ETO gene, which encodes a zinc-fingercontaining transcription factor, in t(8;21)(q22;q22)-associated de novo AML (M2) (Miyoshi et al., 1991; Erickson et al., 1994) . In addition to the AME fusion, the t(3;21)(q26;q22) translocation may result in an inframe fusion of AML1 to MDS1, producing an AML1/ MDS1 chimeric protein and an out-of-frame fusion of AML1 to the EAP gene, resulting in a protein similar to an alternative spliced form of AML1 without the transactivation domain (AML1a) (Nucifora et al., 1994) . The CBFb gene has also been frequently found to be fused to the MYH11 gene, which encodes the smooth muscle myosin heavy chain (SMMHC), in inv(16)(p13;q22)-associated AML (M4Eo) as well as in some cases of CML in the blast phase (Liu et al., 1993; Myint et al., 1997) . Aberrant expression of EVI1 has been found in some CML-BC, MDS and AML that are associated with the t(3;3)(q21q26) and inv(3)(q21q26) chromosome abnormalities (Nucifora, 1997) . In addition, aberrant expression of EVI1 or MDS1/EVI1 has also been frequently found in AML, MDS and other hematological malignancies without detectable chromosomal rearrangement (Russell et al., 1994; Langabeer et al., 2001) . Although AML1-related oncogenes have been shown to function as dominant-negative alleles of normal AML1 (Castilla et al., 1996; Yergeau et al., 1997; Okuda et al., 1998) and EVI1 may block erythroid differentiation (Kreider et al., 1993; Louz et al., 2000) , their exact roles in leukemogenesis are not understood.
To further elucidate the mechanism of the cooperation of AME and BCR/ABL in leukemogenesis and to identify common molecular mechanisms in the pathogenesis of myeloblastic leukemia, we went on to examine the leukemogenic potential of AML1-and EVI1-related oncogenes and their ability to cooperate with BCR/ABL in the pathogenesis of leukemia. We found that both the AML1 and EVI1 oncogenic components contribute to the cooperation of AME with BCR/ABL in blocking myeloid cell differentiation and induction of myeloblastic leukemia.
Results
Expression of EVI1 or MDS1/EVI1 impairs normal hematopoiesis, but only EVI1 can induce hematologic neoplasia in mice with a low efficiency Since aberrant expression of EVI1 has been implicated in causing myeloid leukemia in both humans and mice, and the disruption of CBF function by AML1-related oncogenes, AML1/ETO and CBFb/MYH11, has been found insufficient to induce AML in mice (Nucifora, 1997; Castilla et al., 1999; Louz et al., 2000; Yuan et al., 2001) , we wondered whether the leukemogenic potential of AME is largely attributed to its EVI1 portion and whether there are differences in leukemogenic potential between EVI1 and MDS1/EVI1 in vivo. A previous study using transgenic mice expressing EVI1 under the hematopoietic progenitor-specific sca1 promoter has shown that EVI1 is insufficient to induce AML in mice (Louz et al., 2000) . However, induction of hematologic disorders in patients may require a constitutive expression of EVI1 not only in progenitor cells but also in committed myeloid cells. We, therefore, went to investigate the leukemogenic potential of EVI1 using a bone marrow retroviral transduction and transplantation approach.
Similar to our previous studies of AME, we cloned EVI1 or MDS1/EVI1 cDNA into a bicistronic MSCV retroviral vector with GFP ( Figure 1a ). Western blot analysis of cell lysates from infected NIH3T3 cells demonstrated that the myc-tagged-MDS1/EVI and -EVI1 proteins were expressed (Figure 1b) . We then examined the effect of EVI1 and MDS1/EVI1 expression in hematopoietic cells by transplanting mouse bone marrow cells transduced with equal titers of GFP þ MDS1/EVI1, GFP þ EVI1, and GFP retroviruses into syngeneic recipients. We found that a total of 13 mice that received bone marrow cells transduced with GFP þ MDS1/EVI1 retrovirus (GFP þ MDS1/ EVI1 mice) did not develop any disease up to 18 months post bone marrow transplantation (post-BMT), except for one that died of unknown cause. In contrast, four out of 12 mice that received bone marrow cells transduced with the GFP þ EVI1 retrovirus (GFP þ EVI1 mice) did develop diseases (described below) between 41 and 138 days post-BMT. The rest of the GFP þ EVI1 mice did not have any disease up to 18 months post-BMT, except for one that was sacrificed due to a severe skin infection.
To assess the effect of EVI1 or MDS1/EVI1 on longterm hematopoiesis, we examined by flow cytometry the bone marrow and spleen cells of GFP control, GFP þ EVI1 and GFP þ MDS1/EVI1 mice that had no sign of disease at 8 months post-BMT. Our flow cytometry analyses demonstrated that while the GFP control mice harbored cells with both high and low GFP expression, only cells with low GFP expression could be detected in GFP þ MDS1/EVI1 and GFP þ EVI1 mice (Figure 2a) . Although protein levels of EVI1 or MDS1/ EVI1 were difficult to measure by Western blot in the GFP þ MDS1/EVI1 and GFP þ EVI1 mice due to the limited amount of infected cells present, the GFP expression levels suggest that high expression of either EVI1 or MDS1/EVI1 might be toxic in hematopoietic cells, a phenomenon also previously observed for AME (Cuenco and Ren, 2001) .
To compare the proportion of various lineage marker þ /GFP þ cells from GFP þ MDS1/EVI1 or GFP þ EVI1 mice versus GFP mice in detail, we examined the amount of lineage marker þ /GFP þ cells from each mouse (Figure 2a and data not shown). We also calculated the ratio of the percentage of lineage marker þ /GFP þ cells in the total GFP þ cell population to that of the percentage of lineage marker þ /GFP À cells in the total GFP À cell population (noninfected normal hematopoietic cells) for each mouse. If the ectopic expression of a protein does not affect normal hematopoiesis, then the expected ratio should be equal or close to one, which was the case for most of the average ratios in the GFP vector control mice (Figure 2b ). Interestingly, the proportions and total amounts of
(an early hematopoietic cell marker) cells in both the bone marrow and spleen of GFP þ EVI1 and GFP þ MDS1/ EVI1 mice were significantly increased when compared to those of GFP control mice ( Figure 2 ). There was also a significant decrease in the proportion of Ter119 þ (an erythroid lineage marker) cells in the bone marrow, but not in the spleen of these mice ( Figure 2b ). No significant changes were observed in the proportions of B220 þ (a B-cell marker) and CD3/4/8 þ (T-cell markers) lymphoid cells. These results demonstrate that aberrant expression of either EVI1 or MDS1/EVI1 enhances the growth of myeloid and immature progenitor cells and suppresses erythropoiesis in the bone marrow. However, neither EVI1 nor MDS1/EVI1 blocks myeloid cell differentiation. These data also imply that MDS1 sequences do not affect the activities of EVI1 in regulating hematopoiesis. Interestingly, EVI1 but not MDS1/EVI1, induced diseases in a subset of recipient mice, although none of them developed AML as AME mice did. Among the four diseased GFP þ EVI1 mice, two died at 41 and 56 days post-BMT (#36 and #30, respectively). At the time of death, both mice suffered from bloody pleural effusion that contained a large amount of lymphoblastic cells. Flow cytometry analyses of cells from the pleural effusion, peripheral blood, bone marrow and spleen of one of these mice (mouse #30) showed that most of the GFP þ cells were CD19 þ , B220 lo and c-kit lo , indicating that the mice succumbed to an acute B-lymphoblastic leukemia (B-ALL) ( Figure 3 ). It is worth noting that the leukemic cells in this GFP þ EVI1 mouse had high EVI1 expression (as reflected by high GFP fluorescence intensity). This suggests that high expression of EVI1 may be tolerated in some lymphoid target cells and be required for transforming such cells.
Another GFP þ EVI1 mouse (#39) was moribund and sacrificed at 126 days post-BMT. At this time, this mouse had a high peripheral white blood cell (WBC) count (240 000 cells/ml) and a large lymphoma on its hind limb. In contrast to mouse #30 described above, mouse #39 did not develop pleural effusion. Flow cytometry analyses of the peripheral blood, bone marrow and spleen of mouse #39 revealed that most GFP þ cells also expressed a high level of GFP and that most of them were Mac-1 þ and B220 þ /lo , but negative for CD19 and Gr-1. The lymphoma found in mouse #39 only contained 20% GFP þ cells, which were all B220 þ , but only about half of them were also CD19 þ (data not shown). These results suggest that the GFP þ EVI1 mouse #39 developed either a mixed lineage leukemia or a lymphoid malignancy with a block in early B-cell development.
The last diseased GFP þ EVI1 mouse (#32) in this experiment developed a fatal MPD at 138 days post-BMT (Figure 3 ). Compared to BCR/ABL-induced MPD, this GFP þ EVI1 mouse contained a higher percentage of c-Kit þ cells, indicating that there was some level of accumulation of early progenitor cells. Interestingly, the myeloid tumor cells in this mouse expressed a low level of GFP. The low efficiency and overall long disease latency of the EVI1-induced leukemia shown here suggest that additional mutation(s) may be required for EVI1 leukemogenesis and that the type of secondary mutation(s) may influence the lineage specificity of the disease. þ cell population to that of GFP À cell population in the bone marrow and spleen of GFP, GFP þ MDS1/ EVI1 and GFP þ EVI1 mice. Asterisks above bars indicate P-value of o 0.005 in an unpaired t-test comparing ratios from GFP and GFP þ MDS1/EVI1 or GFP þ EVI1 mice
Coexpression of EVI1 or MDS1/EVI1 with BCR/ABL/ GFP predominantly induces a fatal MPD
To further examine the leukemogenic potential of EVI1 and MDS1/EVI1 when coexpressed with BCR/ABL, we cloned EVI1 or MDS1/EVI1 cDNA into a bicistronic MSCV retroviral vector with the BCR/ABL/GFP fusion gene (Figure 1a) . The fusion of GFP to BCR/ABL facilitated titering of retroviruses and tracking of virusinfected cells while allowing the coexpression of BCR/ ABL and another transgene in the bicistronic retroviral vector. We have previously shown that BCR/ABL/GFP still induces a CML-like MPD at a similar rate as wildtype BCR/ABL under the experimental conditions used (Cuenco and Ren, 2001) . Western blot analysis of whole-cell lysates from infected NIH3T3 cells demonstrated that, although the expression of myc-tagged-MDS1/EVI1 and -EVI1 proteins was not affected by coexpression with BCR/ABL/GFP (Figure 1c) , the BCR/ABL/GFP expression level was significantly reduced when coexpressed with either EVI1 or MDS1/ EVI1 (Figure 1d , comparing lane 2 with lanes 6 and 7). This effect of EVI1 or MDS1/EVI1 on downregulating BCR/ABL is similar to that of AME (Figure 1d,  comparing lanes 2 and 3) .
The leukemogenic potential of BCR/ABL/ GFP þ EVI1 and BCR/ABL/GFP þ MDS1/EVI1 was then examined by the bone marrow transduction and transplantation approach described above. BCR/ABL/ GFP þ AME was included in this experiment as the positive control. We found that both BCR/ABL/ GFP þ EVI1 and BCR/ABL/GFP þ MDS1/EVI1 induced a fatal disease in mice with latencies slightly longer than that induced by BCR/ABL/GFP þ AME (Figure 4a ). The latency of the BCR/ABL/GFP þ AME mice in this study was shorter than what we have previously reported (between 36 and 147 days) most likely due to the higher retroviral titers used (see Materials and Methods) (Cuenco and Ren, 2001 ). The longer disease latencies of these three groups of mice compared to the BCR/ABL/GFP alone mice is likely due to the lower level of BCR/ABL/GFP expression when coexpressed with AME, MDS1/EVI or EVI1, since we have previously found that lower expression of BCR-ABL alone due to different expression vectors does extend the latency of BCR/ABL-induced disease, Figure 3 Immunophenotyping of leukemic cells from diseased GFP þ EVI1 mice. Cells were stained with antibodies to cell surface markers B220, CD19, Mac-1, Gr-1 and c-kit. PB, peripheral blood; PE, pleural effusion; SP, spleen but does not affect the ability of BCR/ABL to induce the CML-like MPD in mice (Hao and Ren, 2000) . The coexpression of both BCR/ABL/GFP and myc-tagged-MDS1/EVI1 or myc-tagged-EVI1 proteins in affected cells could be detected by Western blot in the total lysates of peripheral blood WBCs of BCR/ABL/ GFP þ MDS1/EVI1 and BCR/ABL/GFP þ EVI1 mice (Figure 4b) .
More important than different disease latencies, the disease phenotype of BCR/ABL/GFP þ EVI1 and BCR/ABL/GFP þ MDS1/EVI1 mice was dramatically different from that of BCR/ABL/GFP þ AME mice. Similar to what has previously been shown (Cuenco and Ren, 2001 ), most of the BCR/ABL/GFP þ AME (eight out of 10) mice died of AML, characterized by an anemia and accumulated myeloid blast/immature cells in the peripheral blood, bone marrow and spleen. Flow cytometry analyses of the peripheral blood WBCs of BCR/ABL/GFP þ AME mice showed that most of the GFP þ cells were Mac-1 À/lo and Gr-1 À/lo (Figure 4c ) -consistent with the immature morphology seen on their blood smears (data not shown). In contrast, most of the BCR/ABL/GFP þ EVI1 (seven out of 10) and BCR/ ABL/GFP þ MDS1/EVI1 (eight out of 10) mice died of a fatal MPD, characterized by elevated WBC counts (4100 000 cells/ml), hepatosplenomegaly and pulmonary hemorrhages. Flow cytometry analyses demonstrated that most GFP þ cells in the peripheral blood WBCs of these mice were Mac-1 þ and Gr-1 hi -a typical phenotype of granulocytes (Figure 4c ).
However, different from BCR/ABL/GFP alone mice, a small but significant amount of Gr-1 lo cells in the peripheral blood of BCR/ABL/GFP þ EVI1 and BCR/ ABL/GFP þ MDS1/EVI1 mice showed a diffuse staining pattern (Figure 4c ). This diffuse staining pattern for Gr-1 was previously observed only in the bone marrow and spleen of BCR/ABL/GFP mice (Cuenco and Ren, 2001) . The amount of Gr-1 lo cells varied (ranging from 3 to 16%), but all of the BCR/ABL/GFP þ EVI1 and BCR/ABL/GFP þ MDS1/EVI1 mice that suffered from MPD showed this phenotype. Cytospin analysis of sorted GFP þ /Gr-1 lo cells from the peripheral blood of moribund BCR/ABL/GFP þ EVI1 mice revealed that these are a mixed population of late myelocytes, metamyelocytes and monocytes (data not shown). These results suggest that both EVI1 and MDS1/EVI1 can slightly inhibit the maturation of myeloid cells in BCR/ ABL-induced MPD.
Although the majority of BCR/ABL/GFP þ EVI1 and BCR/ABL/GFP þ MDS1/EVI1 mice developed a fatal MPD with an increased amount of immature cells and the majority of BCR/ABL/GFP þ AME mice suffered from an AML, there were exceptions. Three out of 10 BCR/ABL/GFP þ EVI1 mice and two out of 10 BCR/ABL/GFP þ MDS1/EVI1 mice developed a mixed lymphoid and myeloid leukemia, but most likely died of pleural effusion -a phenotype typically observed in mice with B-ALL (Figure 4d and data not shown). In addition, one mouse from each of the BCR/ ABL/GFP þ EVI1 and BCR/ABL/GFP þ MDS1/EVI1 Figure 4 Survival, Western blot and flow cytometry analyses of BCR/ABL/GFP þ AME, BCR/ABL/GFP þ MDS1/EVI1 and BCR/ ABL/GFP þ EVI1 mice. (a) Kaplan-Meier survival analysis of GFP (four mice), BCR/ABL/GFP (five mice), BCR/ABL/GFP þ AME (10 mice), BCR/ABL/GFP þ MDS1/EVI1 (10 mice) and BCR/ABL/GFP þ EVI1 (10 mice) mice. (b) Western blot analysis of total cell lysates of peripheral blood from diseased BCR/ABL/GFP þ MDS1/EVI1 and BCR/ABL/GFP þ EVI1 mice probed with an anti-myc (9E10) or anti-abl (AB3) antibody. All blots were stripped and reprobed with an anti-dynamin antibody for loading control. (c) Flow cytometry analysis of peripheral blood WBCs from diseased BCR/ABL/GFP, BCR/ABL/GFP þ AME, BCR/ABL/GFP þ MDS1/ EVI1 and BCR/ABL/GFP þ EVI1 mice. Cells were stained with antibodies to cell surface markers Mac-1 and Gr-1. (d) Flow cytometry analysis of diseased BCR/ABL/GFP þ EVI1 mouse #26 that suffered from B-cell leukemia/lymphoma. Cells from the peripheral blood (PB), pleural effusion (PE) and tumor were stained with antibodies to cell surface markers Mac-1 and Gr-1 and B220 mouse groups also had a large lymphoma in the abdominal cavity. The tumors contained mostly GFP þ /B220 þ B-lymphoid cells (Figure 4d ). In addition, two out of 10 BCR/ABL/GFP þ AME mice developed a fatal MPD instead of AML -a phenomenon also observed previously due to a loss of AME expression (Cuenco and Ren, 2001) . Despite these exceptions, EVI1 and MDS1/EVI1 clearly lack the ability possessed by AME to cooperate with BCR/ABL in the rapid induction of AML.
Coexpression of AML1D or AML1/MDS1 with BCR/ ABL/GFP still induces a fatal MPD
Since the EVI1 or MDS/EVI1 part of AME was not sufficient to cooperate with BCR/ABL in the rapid induction of AML, we went on to investigate the role of the AML1 part of AME in the BCR/ABL/ GFP þ AME-induced AML. We first examined the effect of AML1D (the AML1 part of AME, similar to AML1a and AML1/EAP) and AML1/MDS1 in mouse hematopoietic cells when coexpressed with BCR/ABL. As shown in Figure 1a , we cloned AML1D or AML1/MDS1 into a bicistronic MSCV retroviral vector with either GFP or BCR/ABL/GFP fusion gene. Figure 1 shows that the myc-tagged-AML1D and AML1/MDS1 proteins were expressed in infected NIH3T3 cells when coexpressed with either GFP (Figure 1b) or BCR/ABL/GFP fusion (Figure 1c) . Different from coexpression with AME, MDS1/EVI1 and EVI1 (described above), the expression of BCR/ ABL/GFP was not affected by coexpression with AML1D or AML1/MDS1 (Figure 1d , comparing lane 2 with lanes 4 and 5).
We then examined the leukemogenic potential of BCR/ABL/GFP þ AML1D and BCR/ABL/GFP þ AML1/MDS1 using the mouse bone marrow transduction and transplantation system. We found that similar to BCR/ABL/GFP alone, both BCR/ABL/GFP þ AML1D and BCR/ABL/GFP þ AML1/MDS1 induced a fatal MPD (Figure 5a ). However, there was a slight extension in the disease latency of BCR/ABL/ GFP þ AML1D and BCR/ABL/GFP þ AML1/MDS1 mice when compared to BCR/ABL/GFP-alone mice. Mantel-Cox rank test analysis comparing the survival of BCR/ABL/GFP to BCR/ABL/GFP þ AML1D or BCR/ABL/GFP þ AML1/MDS1 mice resulted in Pvalues of 0.0002 and 0.0001, respectively. The expression of both BCR/ABL/GFP and myc-tagged-AML1D or myc-tagged-AML1/MDS1 proteins in affected cells could be detected by Western blot in the total lysates of peripheral blood of BCR/ABL/GFP þ AML1D and BCR/ABL/GFP þ AML1/MDS1 mice (Figure 5b ). These results demonstrate that AML1D or AML1/ MDS1 is not sufficient to cooperate with BCR/ABL/ GFP in the induction of AML. However, the significant extension of disease latencies of BCR/ABL/ GFP þ AML1D and BCR/ABL/GFP þ AML1/MDS1 mice indicates that AML1 may attenuate the BCR/ ABL-induced MPD by a mechanism other than lowering BCR/ABL expression. (Figure 5c ). However, slightly different from BCR/ABL/GFP mice, the peripheral blood of all of the BCR/ABL/GFP þ AML1D and BCR/ABL/ GFP þ AML1/MDS1 mice showed a diffuse immunostaining pattern of the Gr-1 marker in about 10% of GFP þ /Gr-1 þ cells (Figure 5c ). Cytospin analysis of sorted GFP þ /Gr-1 lo cells from the peripheral blood of moribund BCR/ABL/GFP þ AML1D mice showed that these cells are a mixed population of late myelocytes, metamyelocytes and monocytes (data not shown). These results suggest that the coexpression of either AMLD or AML1/MDS1 with BCR/ABL/GFP also inhibits the maturation of myeloid cells in BCR/ABL-induced MPD.
Discussion
Mutations of AML1 and aberrant expression of EVI1, with or without 3q21q26 rearrangement, has both been frequently found in human AML. It has been previously shown that AML1-related oncogenes, AML1/ETO and CBFb/MYH11, are not sufficient to induce AML in mice by themselves. In this study, we showed that the ectopic expression of either EVI1 or MDS1/EVI1 causes minor impairments in hematopoiesis and that EVI1, but not MDS1/EVI1, has a weak leukemogenic potential. However, when expressed alone, EVI1-related oncogenes cannot induce AML in mice as AME does. These results demonstrate that induction of AML by AME requires functions and/or functional cooperation of both AML1 and EVI1 oncogenic components. In addition, like AME, AML1/ETO, CBFb/MYH11 and overexpression of EVI1 have all been found in some cases of CML in the blast phase (Myint et al., 1997; Nucifora, 1997; Kojima et al., 1999) . However, although AML1-and EVI1-related oncogenes studied here inhibit the maturation of myeloid cells in BCR/ABL-induced MPD to some extent, they are not sufficient to cooperate with BCR/ABL in the induction of AML in mice as AME does. These results demonstrate that cooperation between AME and BCR/ABL in the rapid induction of AML also requires both AML1 and EVI1 oncogenic components.
The conclusion that EVI1 is insufficient to induce AML in mice is consistent with a previous study using transgenic mice expressing EVI1 under the hematopoietic progenitor-specific sca1 promoter, which developed myeloid leukemia only when additional mutation(s) were introduced by infecting the newborn sca1-EVI1 transgenic mice with the CAS-Br-M MuLv retrovirus (Louz et al., 2000) . The activity of EVI1 in inhibiting erythropoiesis in our model is also in agreement with that found in the sca1-EVI1 transgenic mice, as well as with another previous findings that the ectopic expression of EVI1 in erythroid progenitors results in a loss of their responsiveness to erythropoietin (Kreider et al., 1993) . However, our data showed that although EVI1 or MDS1/EVI1 suppresses erythropoiesis in the bone marrow, they seem to enhance erythropoiesis in the spleen (Figure 2b ). This result suggests that the environments for erythropoiesis in the bone marrow and spleen are different and that the spleen erythropoietic environment may overcome the defect caused by expression of EVI1. Different from our model, the low penetrant hematological malignancies were not found in the sca-1-EVI1 transgenic mice. In addition, different from previous studies, our data also demonstrate that EVI1 can augment the expansion of cells of granulocytic lineage. This activity of EVI1 may predispose the myeloid cells to the development of AML upon acquisition of additional mutations. These latter differences between the two animal models may be due to different levels of EVI1 expression and/or due to targeting of EVI1 in different hematopoietic cells. In particular, the expression of EVI1 under the control of progenitor-specific sca1 promoter may differ from that in EVI1-associated AML.
We have found previously that coexpression of AME reduced the expression of BCR/ABL/GFP (Cuenco and Ren, 2001 ). Here, we have shown that coexpression of EVI1 or MDS1/EVI1 also caused a reduced expression of BCR/ABL/GFP (Figure 1d ). In contrast, BCR/ABL/ GFP expression was not affected by coexpression of AML1-related oncoproteins. Together, these results indicate that EVI1 has a specific activity that can lead to the downregulation of BCR/ABL protein expression and that this activity of EVI1 is not affected by the addition of AML1 and/or MDS1 sequences. The lower expression of BCR/ABL/GFP in EVI1-containing oncogene mice may account for the longer disease latency as compared to that of BCR/ABL/GFP alone mice (Figure 4a ). Indeed, we have previously shown that lower expression of BCR/ABL alone due to different expression vectors does extend the latency of BCR/ ABL-induced disease, but does not affect the ability of BCR/ABL to induce the CML-like MPD in mice (Hao and Ren, 2000) . The differences in disease phenotypes between BCR/ABL/GFP þ AME and BCR/ABL/ GFP þ MDS1/EVI1 or BCR/ABL/GFP þ EVI1 mice indicate that, unlike AME, EVI1 and MDS1/EVI1 only have a weak potential to cooperate with BCR/ABL in interfering with myeloid differentiation/maturation, but are insufficient to cooperate with BCR/ABL in inducing AML. The inability of EVI1 and MDS1/EVI1 to cooperate with BCR/ABL in the induction of AML further confirms that the cooperation between AME and BCR/ABL in the rapid induction of AML is specific and not due to a lower expression of BCR/ABL. MDS1/EVI1, an alternatively spliced form of EVI1, contains an additional 188 amino-acid (AA) residues upstream of EVI1 (Nucifora, 1997) . These added sequences and the NH 2 -terminus of EVI1 together form a PR domain, which is present in a subclass of zincfinger proteins, which appear to function as negative regulators of tumorigenesis (Huang et al., 1998) . It has been shown that MDS1/EVI1, in contrast to EVI1 and AME, does not block the antiproliferative effect of TGFb and does not block granulocytic differentiation of the IL-3-dependent 32D cell line when stimulated with granulocyte colony-stimulating factor (G-CSF) (Tanaka et al., 1995; Sood et al., 1999) . These data suggest that the PR domain of MDS1/EVI1 may inhibit EVI1 functions. In this study, we found that MDS1/EVI1 has the same activity as EVI1 in impairing hematopoiesis, downregulating BCR/ABL/GFP and inhibiting the maturation of myeloid cells in BCR/ABL-induced MPD (Figures 1, 2 and 4) . However, it differed from EVI1 by its inability to induce hematological neoplasia by itself. Our data suggest that EVI1 has at least two sets of oncogenic functions -one that dysregulates hematopoiesis and the other regulates cell growth (proliferation, survival or both). MDS1, or the PR domain, may modulate the function of EVI1 in promoting cell growth, but it does not seem to affect the function of EVI1 in impairing hematopoiesis.
Several studies have indicated that AME retains both AML1-and EVI1-derived oncogenic functions. Competitive inhibition assays have shown that AME, like AML1-related oncoproteins, dominantly inhibits AML1/RUNX1-induced transactivation (Tanaka et al., 1995) . This function of AME may inhibit the expression of CBF target genes, such as tumor suppressor gene(s) as well as genes important for hematopoiesis. On the other hand, AME, like EVI1, can abrogate TGFb signaling by interacting with and inhibiting Smad3 and can also stimulate c-fos promoter transactivation and increase AP-1 activity (Tanaka et al., 1995; Kurokawa et al., 1998) . It has also been shown recently that AME, similar to EVI1, can interact with the corepressor CtBP1 (Izutsu et al., 2002; Senyuk et al., 2002) . In addition, the fusion between the AML1 and EVI1 oncogenes may also generate fusion-specific functions. Some or all of these functions may cooperate in leukemogenesis.
The presence of both signaling type and transcription factor type of oncoproteins is a common theme in myeloblastic leukemia (including both AML and CML-BC). It seems that BCR/ABL-induced activation of protein tyrosine kinase pathways is sufficient to induce MPD, possibly by stimulating myeloid cell proliferation and enhancing cell survival. Our data here demonstrate that both the AML1 and EVI1 oncogenic components of AME are required for the cooperation of AME and BCR/ABL in the induction of AML. The data imply that not all types of transcription factor oncogenes are sufficient to cooperate with an activated protein tyrosine kinase in the induction of AML and that the block of myeloid cell differentiation is a complex process in the pathogenesis of myeloblastic leukemia. Further elucidating the common molecular mechanism of this process will help develop effective therapies.
Materials and methods

DNA constructs
The GFP cDNA was fused to the C-terminal end of BCR/ABL and cloned into the EcoRI site of the MSCV retroviral vector as previously described (Cuenco and Ren, 2001) . Figure 1a shows a schematic diagram of all constructs used in this study. Cloning of the MSCV-IRES-GFP and MSCV-GFP-IRES-myc tag-AME constructs was as described (Cuenco et al., 2000) .
All AME-related mutants were cloned downstream of the IRES sequence followed by two myc tag sequences and were coexpressed with either GFP or BCR/ABL/GFP fusion in the MSCV retroviral vector. The AML1 mutant was made by PCR amplifying the first 767 bp of the AME cDNA (AA 1-256 of AME, which is the junction of AML1 and MDS1) to add a NotI site at the 5 0 end and to add two in-frame stop codons and a ClaI site at the 3 0 end. The same 5 0 and 3 0 additions were made to the AML1/MDS1 mutant, except that the first 1103 bp of the AME cDNA (AA 1-368 of AME) was PCR amplified. Both AML1D and AML1/MDS1 were cloned into the NotI and ClaI sites of MSCV. The MDS1/EV11 mutant was made by adding a 39 bp sequence on its 5 0 end (the t(3;21) breakpoint in AME fusion removes the first 13AA on the NH 2 terminus of MDS1) by PCR using AME cDNA as a template. A 382 bp PCR product flanked with NotI on its 5 0 end and BglII on its 3 0 end was ligated with the EVI1-containing fragment of 3347 bp flanked with BglII on its 5 0 end and ClaI on its 3 0 end. This 3.7 kb cDNA (13AA of MDS1 þ AA256-1494 of AME) was cloned into the NotI and ClaI sites of MSCV. The EVI1 mutant (AA432-1494 of AME -uses natural start site on exon 3 of EVI1) was made amplifying nucleotides #1293-2993 of AME by PCR to add a NotI site on its 5 0 end. The 1.7 kb PCR product was digested with NotI and PshAI and ligated to a 1.5 kb fragment flanked with PshAI and ClaI on its 5 0 and 3 0 ends, respectively, and to the NotI and ClaI sites of MSCV.
Retrovirus preparation We have previously found that the retroviral titer of the MSCV-BCR/ABL/GFP-IRES-myc tag-AME construct is low due to the large genome size of the retrovirus (B14 kb) (Cuenco and Ren, 2001) . Therefore, to increase retroviral titers for this study, we cotransfected BOSC23 cells with 5 mg of each and all of the constructs described in Figure 1a with 1 mg of the helper packaging vector pCL-Eco (Naviaux et al., 1996) . As in our previous studies, we estimated the retroviral titers by measuring the amount of infected NIH3T3 cells through quantitation of %GFP þ cells by flow cytometry. We compared titers of retroviruses made with or without pCL-Eco using the MSCV-BCR/ABL/ GFP-IRES-myc tag-AME construct and found that titers improved from less than 10% to as high as 50% GFP Bone marrow transduction and transplantation Bone marrow cells from 5-fluorouracil-treated Balb/C mice were isolated, infected and transplanted into syngeneic recipient mice as previously described (Zhang and Ren, 1998) .
Blood cell counts, flow cytometry and Western blot analysis Peripheral blood counts of recipient mice were counted starting from 2 weeks after transplantation as described (Cuenco et al., 2000) . Cells from peripheral blood, bone marrow and spleen were processed and stained with PE-or APC-conjugated mouse antibodies (Pharmingen) for flow cytometry as previously described (Cuenco et al., 2000) . A total of 100 000 events were collected using the FACSCALI-BUR (Becton Dickinson) for assessing the effect of MDS1/ EVI1 and EVI1 on hematopoiesis. The ratio of the percentage of lineage marker þ /GFP þ cells in total GFP þ cell population to that of the percentage of lineage marker þ /GFP À cells in the total GFP À cell population was calculated as described (Cuenco and Ren, 2001) . Total cell lysates from peripheral blood of diseased mice were processed for Western blot as described (Cuenco et al., 2000) .
